Real-world evidence (RWE) shows that HIV-associated wasting (HIVAW) remains a significant comorbidity
10 March 2021
- A first retrospective, RWE study investigating HIVAW in more than 10 years suggests the condition remains a significant comorbidity despite modern antiretroviral therapy (ART).
- Results showed the overall prevalence of HIVAW in the study of 42,587 HIV+ patients was 18.3%.
- “Many physicians consider HIV-associated wasting no longer an existing comorbidity in the era of modern ART, but the evidence suggests otherwise and the continued need for on-going assessments of people living with HIV for weight loss,” said Javeed Siddiqui, MD, MPH, Chief Medical Officer of TeleMed2U
Click here to learn more.
About SVMPharma
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
ref: MAR2021CW001